Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dacomitinib

FDA-approved product (tablet, oral), marketed as Vizimpro.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Dacomitinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dacomitinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dacomitinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluate Severe Hepatic Impairment on Dacomitinib PK

    NCT03865446 · start 2019-04-05

    Registered record
    Registry ID
    NCT03865446
    Conditions
    Severe Hepatic Impairment
    Interventions
    Dacomitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-04-05
    Completion
    2019-10-24
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Hepatic Impairment
    InterventionDacomitinib
    PhasePhase 1
    Registry statusCompleted

  • Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer

    NCT03810807 · start 2019-01-17

    Registered record
    Registry ID
    NCT03810807
    Conditions
    Metastatic Non-small Cell Lung Cancer
    Interventions
    Dacomitinib; Osimertinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-01-17
    Completion
    2025-12-15
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Non-small Cell Lung Cancer
    InterventionDacomitinib; Osimertinib
    PhasePhase 1
    Registry statusCompleted

  • A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.

    NCT03755102 · start 2018-11-21

    Registered record
    Registry ID
    NCT03755102
    Conditions
    EGFR Gene Mutation; Lung Cancer; Lung Cancer Metastatic
    Interventions
    Dacomitinib; Osimertinib
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2018-11-21
    Completion
    2023-07-07
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEGFR Gene Mutation; Lung Cancer; Lung Cancer Metastatic
    InterventionDacomitinib; Osimertinib
    PhaseEarly phase 1
    Registry statusCompleted

  • A Rollover Protocol of Dacomitinib For Patients In Japan

    NCT02382796 · start 2015-07-10

    Registered record
    Registry ID
    NCT02382796
    Conditions
    NSCLC
    Interventions
    Dacomitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-07-10
    Completion
    2019-05-30
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC
    InterventionDacomitinib
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer

    NCT02268747 · start 2014-11

    Registered record
    Registry ID
    NCT02268747
    Conditions
    Skin Squamous Cell Cancer
    Interventions
    Dacomitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2014-11
    Completion
    2016-11
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Squamous Cell Cancer
    InterventionDacomitinib
    PhasePhase 2
    Registry statusUnknown

  • Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC

    NCT02039336 · start 2014-04-02

    Registered record
    Registry ID
    NCT02039336
    Conditions
    Colorectal Cancer
    Interventions
    Dacomitinib; PD-0325901; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2014-04-02
    Completion
    2018-08-07
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionDacomitinib; PD-0325901; Docetaxel
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • A Phase II Study of Dacomitinib in Progressive Brain Metastases

    NCT02047747 · start 2014-02

    Registered record
    Registry ID
    NCT02047747
    Conditions
    Brain Cancer
    Interventions
    Dacomitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2014-02
    Completion
    2016-02
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain Cancer
    InterventionDacomitinib
    PhasePhase 2
    Registry statusTerminated

  • A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

    NCT01920061 · start 2013-09-10

    Registered record
    Registry ID
    NCT01920061
    Conditions
    Neoplasm
    Interventions
    PF-05212384 (gedatolisib); Docetaxel; Cisplatin; Dacomitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-09-10
    Completion
    2020-01-08
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasm
    InterventionPF-05212384 (gedatolisib); Docetaxel; Cisplatin; Dacomitinib
    PhasePhase 1
    Registry statusCompleted

  • Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)

    NCT01918761 · start 2013-07-30

    Registered record
    Registry ID
    NCT01918761
    Conditions
    Non Small Cell Lung Cancer
    Interventions
    Dacomitinib, Pemetrexed
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2013-07-30
    Completion
    2016-09-15
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer
    InterventionDacomitinib, Pemetrexed
    PhasePhase 1
    Registry statusTerminated

  • Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis

    NCT01728233 · start 2013-06-15

    Registered record
    Registry ID
    NCT01728233
    Conditions
    Penile Neoplasms; Carcinoma, Squamous Cell
    Interventions
    Dacomitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-06-15
    Completion
    2018-09-21
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPenile Neoplasms; Carcinoma, Squamous Cell
    InterventionDacomitinib
    PhasePhase 2
    Registry statusCompleted

  • Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck

    NCT01737008 · start 2013-01

    Registered record
    Registry ID
    NCT01737008
    Conditions
    Squamous Cell Carcinoma of the Head and Neck
    Interventions
    dacomitinib; Radiotherapy; Cisplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-01
    Completion
    2015-05
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSquamous Cell Carcinoma of the Head and Neck
    Interventiondacomitinib; Radiotherapy; Cisplatin
    PhasePhase 1
    Registry statusCompleted

  • A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus

    NCT01608022 · start 2012-07

    Registered record
    Registry ID
    NCT01608022
    Conditions
    Esophageal Squamous Cell Carcinoma
    Interventions
    PF804
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-07
    Completion
    2015-10
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEsophageal Squamous Cell Carcinoma
    InterventionPF804
    PhasePhase 2
    Registry statusCompleted

  • A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment

    NCT01571388 · start 2012-04

    Registered record
    Registry ID
    NCT01571388
    Conditions
    Healthy; Otherwise Healthy Volunteers With Mild or Moderate Hepatic Dysfunction
    Interventions
    dacomitinib; dacomitinib; dacomitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-04
    Completion
    2012-08
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy; Otherwise Healthy Volunteers With Mild or Moderate Hepatic Dysfunction
    Interventiondacomitinib; dacomitinib; dacomitinib
    PhasePhase 1
    Registry statusCompleted

  • Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.

    NCT01520870 · start 2012-02

    Registered record
    Registry ID
    NCT01520870
    Conditions
    Glioblastoma; Brain Tumor, Recurrent
    Interventions
    PF-299804 (Dacomitinib)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-02
    Completion
    2017-03-09
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma; Brain Tumor, Recurrent
    InterventionPF-299804 (Dacomitinib)
    PhasePhase 2
    Registry statusCompleted

  • Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

    NCT01465802 · start 2011-12-26

    Registered record
    Registry ID
    NCT01465802
    Conditions
    Non Small Cell Lung Cancer (NSCLC)
    Interventions
    Dacomitinib; Dacomitinib; Doxycycline; Probiotic; Alclometasone cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-12-26
    Completion
    2015-05-18
    Enrolment
    236

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer (NSCLC)
    InterventionDacomitinib; Dacomitinib; Doxycycline; Probiotic +1 more
    PhasePhase 2
    Registry statusCompleted